Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Ataxia Treatment Market size was over USD 850.4 million in 2024 and is estimated to reach USD 2.7 billion by the end of 2037, expanding at a CAGR of 7% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of ataxia treatment is evaluated at USD 910.2 million.
The increasing prevalence and severity of genetic deformities around the world are propelling the demand in the ataxia treatment market. According to the National Institute of Health (NIH), the hereditary ataxias, such as Friedreich’s ataxia (FA) and spinocerebellar ataxia (SCA), affected approximately 1 in 50,001 individuals till 2024. On the other hand, 45,001 cases of ataxia were recorded from across Germany in 2025, which highlighted a 20.1% rise since 2018, as per a report from the Robert Koch Institute (RKI). In addition, the growing burden of comorbidities, including stroke, trauma, and neurodegenerative diseases, is also magnifying the patient pool.
The substantial rise in the key economic indicators reflects continuous inflation in the ataxia treatment market, making it more financially exhausting. To display this upstream flow, in 2024, the Bureau of Labor Statistics (BLS) reported that the producer price index (PPI) for all neurological drugs witnessed a 4.3% annual rise from 2020 to 2024. This was caused by the rising costs related to API and compliance procurement. Subsequently, the increasing burden was also identified in the consumer price index (CPI) for ataxia therapies, with a 6.2% year-over-year (YoY) surge, due to premium pricing trends. Currently, initiatives from insurers, governing bodies, and manufacturers are taken to bring cost-effectiveness in this sector, improving public access.
